Biodesix provides one comprehensive picture of your patient’s cancer from a simple
blood draw to inform treatment decisions throughout the continuum of care

Biodesix discovers, develops and commercializes blood-based tests used by pulmonologists, thoracic surgeons, oncologists, pathologists and other treating physicians for better therapeutic guidance, accurate prognostic information and enhanced disease monitoring to improve patient outcomes. These tests support management of patients with NSCLC through each step of a patient’s care, from diagnosis to therapy guidance and monitoring.

Biodesix Lung Reflex® tests provide actionable genomic and proteomic test results within 72 hours to inform rapid treatment decisions and support prognostic conversations. This innovative testing strategy integrates the GeneStrat® genomic test and the VeriStrat® proteomic test to provide fast, actionable results for patients with NSCLC throughout the continuum of cancer care based on their unique biological makeup.

  1. Sacher AG et al. JAMA Oncol. 2016 Aug 1;2(8):1014-22.
  2. Vidaver RM et al. J Oncol Pract 2016 Jun 3;12(6):e643-53.
  3. ELCC 2015 Press Release: One in Four Advanced Lung Cancer Patients Tested for EGFR Mutations Started on First-line Treatment Before Test Results Available.” ESMO. N.p., 17 Apr. 2015. Web.
  4. Lim C et al. Ann Oncol. 2015 Jul;26(7):1415-21.